Evidence map›Paper›PMID 28948183›Full record

ArticleOpen forum infectious diseases2017

Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients.

Jesús Troya, Guillermo Cuevas, Pablo Ryan, Victorino Díez, Elsa Izquierdo, Ismael Escobar, Javier Solís

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jesús TroyaDepartment of Internal Medicine.
Guillermo CuevasDepartment of Internal Medicine.
Pablo RyanDepartment of Internal Medicine.
Victorino DíezMedical Outpatient Care Unit, and.
Elsa IzquierdoDepartment of Hospital Pharmacy, Hospital Universitario Infanta Leonor, Madrid, Spain.
Ismael EscobarDepartment of Hospital Pharmacy, Hospital Universitario Infanta Leonor, Madrid, Spain.
Javier SolísDepartment of Internal Medicine.
Hospital Universitario Infanta Leonor · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune reconstitution inflammatory syndrome can present as a paradoxical reaction after initiation of antiretroviral treatment in patients with severe immunosuppression and underlying infections. Immune reconstitution inflammatory syndrome has often been associated with mycobacteria, and the clinical response to traditional treatment with corticosteroids is not always satisfactory. Consequently, administration of an infliximab biosimilar could lead to an improvement in the clinical status of these patients.

Indexed as

HIVinfliximab biosimilarIRISmycobacteria

Identifiers

PMID28948183
PMCPMC5604167
OpenAlexW2743665893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.